Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;35(8):1466-1471.
doi: 10.1002/mds.28073. Epub 2020 May 14.

Relationship of Cerebrospinal Fluid Vitamin B12 Status Markers With Parkinson's Disease Progression

Chadwick W Christine  1 , Peggy Auinger  2 , Nasrin Saleh  3 , Miao Tian  3 , Teodoro Bottiglieri  4 , Erland Arning  4 , Nam K Tran  3 , Per Magne Ueland  5 , Ralph Green  3 ; Parkinson Study Group-DATATOP Investigators
Affiliations

Relationship of Cerebrospinal Fluid Vitamin B12 Status Markers With Parkinson's Disease Progression

Chadwick W Christine et al. Mov Disord. 2020 Aug.

Abstract

Background: Using blood specimens from untreated early Parkinson's disease (PD) patients from the DATATOP trial, we found that subjects in the low serum vitamin B12 tertile experienced greater annualized change in ambulatory capacity score, whereas those with moderately elevated (>15 μmol/L) total homocysteine had greater annualized declines in the Mini-Mental State Exam.

Methods: In this this study we sought to determine whether levels of cerebrospinal fluid (CSF) B12 markers were also associated with progression of PD.

Results: The annualized change in the UPDRS "walking" item, a component of the ambulatory capacity score, was worse in the low B12 tertile. No association with change in the Mini-Mental State Exam was seen for those 7% with the highest baseline CSF total homocysteine.

Conclusions: In these untreated early-PD subjects, low CSF B12 predicted greater worsening of the UPDRS "walking" item, whereas CSF total homocysteine was not associated with progression of cognitive impairment. These findings extend and partially support our findings in serum. © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Keywords: CSF; cognitive impairment; cyanocobalamin; gait instability; hyperhomocysteinemia; vitamin B12.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distributions of CSF vitamin B12, MMA, HoloTc and tHcy.
See this image and copyright information in PMC

References

    1. Christine CW, Auinger P, Joslin A, Yelpaala Y, Green R, Parkinson Study Group . Vitamin B12 and homocysteine levels predict different outcomes in early Parkinson's disease. Mov Disord 2018;33:762–770. - PubMed
    1. Parashos SA, Elm J, Boyd JT, et al. Validation of an ambulatory capacity measure in Parkinson disease: a construct derived from the Unified Parkinson's Disease Rating Scale. J Parkinsons Dis 2015;5:67–73. - PMC - PubMed
    1. Jia L, Wang Y, Wei W, Zhao W, Lu F, Liu F. Vitamin B12 inhibits alpha‐synuclein fibrillogenesis and protects against amyloid‐induced cytotoxicity. Food Funct 2019;10:2861–2870. - PubMed
    1. Schaffner A, Li X, Gomez‐Llorente Y, et al. Vitamin B12 modulates Parkinson's disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection. Cell Res 2019;29:313–329. - PMC - PubMed
    1. Mattsson N. CSF biomarkers in neurodegenerative diseases. Clin Chem Lab Med 2011;49:345–352. - PubMed

Publication types